RxDoctor Payments DataLook up a doctor →

Michael Borne, MD

Retina Specialist · Jackson, MSNPI 1588750178

Payments from drug & device makers

$943,157in general payments, 2019–2025

Across 407 payments — averaging $2317.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$408K
  • Boehringer Ingelheim$268K
  • Apellis Pharmaceuticals, Inc.$106K
  • Roche TCRC, Inc.$55K
  • Regeneron Healthcare Solutions, Inc.$41K
  • Regeneron$28K
  • plus $37K from 15 others
$10,650in research payments, 2019–2025

Across 1 payment — averaging $10,650 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ocular Therapeutix, Inc.$11K

What the payments were for

  • Consulting fees$13,1709%
  • Speaking & faculty fees$111,62374%
  • Travel & lodging$11,2847%
  • Food & beverage$6,0244%
  • Gifts$190%
  • Entertainment$680%
  • Ownership interest$3,4102%
  • Other$5,5434%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$6,861,922
Medicare patients
1,494
Services billed
27,184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CombiganBrimonidine Tartrate/Timolol21$9,358
LumiganBimatoprost16$7,607
Prednisolone Acetate178$5,661
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$4,889
Alphagan PBrimonidine Tartrate18$4,216
Ketorolac Tromethamine70$3,204
Travoprost14$2,120
Latanoprost190$1,963
Ofloxacin106$1,280
Brimonidine Tartrate60$1,113
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$585
Timolol Maleate63$541
Dorzolamide Hcl30$529
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha38$418
Flurbiprofen Sodium13$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Lumigan, Alphagan P$599$21,18055 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other retina specialist in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →